This HTML5 document contains 79 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00639/identifier/chemspider/
n25http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/mesh/concept/
n13http://linked.opendata.cz/resource/drugbank/company/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00639/identifier/wikipedia/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00639/identifier/pharmgkb/
n17http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00639/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00639/identifier/pubchem-compound/
n26http://linked.opendata.cz/resource/drugbank/patent/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00639/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00639/identifier/kegg-drug/
n27http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n22http://www.drugs.com/cdi/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00639/identifier/drugbank/
n23http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
n24http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00639/identifier/national-drug-code-directory/
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00639
rdf:type
n3:Drug
n3:description
Butoconazole is an imidazole antifungal used in gynecology.
n3:group
approved
n3:indication
For the local treatment of vulvovaginal candidiasis (infections caused by Candida)
n3:manufacturer
n13:271B5E10-363D-11E5-9242-09173F13E4C5 n13:271B5E0E-363D-11E5-9242-09173F13E4C5 n13:271B5E0F-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00639 n17:DB00639
dcterms:title
Butoconazole
adms:identifier
n12:46508016 n14:47472 n15:D00880 n16:64011-001-08 n18:C08066 n19:43192 n20:DB00639 n29:Butoconazole n30:PA164781353
n3:mechanismOfAction
The exact mechanism of the antifungal action of butoconazole is unknown, however, it is presumed to function as other imidazole derivatives via inhibition of steroid synthesis. Imidazoles generally inhibit the conversion of lanosterol to ergosterol via the inhibition of the enzyme cytochrome P450 14α-demethylase, resulting in a change in fungal cell membrane lipid composition. This structural change alters cell permeability and, ultimately, results in the osmotic disruption or growth inhibition of the fungal cell.
n3:packager
n13:271B5E08-363D-11E5-9242-09173F13E4C5 n13:271B5E09-363D-11E5-9242-09173F13E4C5 n13:271B5E0C-363D-11E5-9242-09173F13E4C5 n13:271B5E0D-363D-11E5-9242-09173F13E4C5 n13:271B5E0A-363D-11E5-9242-09173F13E4C5 n13:271B5E0B-363D-11E5-9242-09173F13E4C5
n3:patent
n26:5266329 n26:5993856
n3:synonym
Compositenstärke Alant starch Butoconazolum Dahlin Butoconazol 1-[4-(4-Chloro-phenyl)-2-(2,6-dichloro-phenylsulfanyl)-butyl]-1H-imidazole Butoconazole Polyfructosanum
n3:toxicity
Oral, rat: LD<sub>50</sub> = >1720 mg/kg.
n9:hasAHFSCode
n25:84-04-08-08
n3:salt
n3:synthesisReference
Laszlo Czibula, Laszlo Dobay, Eva Werkne Papp, Judit Nagyne Bagdy, Ferenc Sebok, "High Purity Butoconazole Nitrate with Specified Particle Size and a Process for the Preparation Thereof." U.S. Patent US20080221190, issued September 11, 2008.
n27:hasConcept
n28:M0067615
foaf:page
n22:butoconazole-cream.html n23:butoconazole.htm n24:myc1567.shtml
n3:IUPAC-Name
n4:271B5E17-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5E1D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5E1C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5E19-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5E1A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5E1B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E15-363D-11E5-9242-09173F13E4C5 n4:271B5E2C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E16-363D-11E5-9242-09173F13E4C5 n4:271B5E13-363D-11E5-9242-09173F13E4C5 n4:271B5E2E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E14-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:G01AF15
n3:H-Bond-Acceptor-Count
n4:271B5E23-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5E24-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5E1E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5E1F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5E21-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5E20-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5E22-363D-11E5-9242-09173F13E4C5
n3:absorption
Following vaginal administration of butoconazole nitrate vaginal cream, 2% to 3 women, 1.7% (range 1.3-2.2%) of the dose was absorbed on average.
n3:affectedOrganism
Fungi, yeast and protozoans
n3:casRegistryNumber
64872-77-1
n3:category
n3:containedIn
n7:271B5E11-363D-11E5-9242-09173F13E4C5 n7:271B5E12-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5E28-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5E2A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5E2B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5E2D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5E27-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5E26-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5E29-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5E18-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5E25-363D-11E5-9242-09173F13E4C5